Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
Lisata Therapeutics to be acquired by Kuva Labs
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Lisata Therapeutics (LSTA) Projected to Post Quarterly Earnings on Thursday
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Lisata regains China rights to pancreatic cancer drug
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasdaq - VTYX)
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal
UK inflation picks up with geopolitics a risks for prices in 2026
Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)
Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.9% – Time to Sell?
Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript
Lisata Therapeutics advances certepetide, inks strategic alliances in Q3
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
Lisata Therapeutics reports preclinical data showing certepetide's potential to enhance cancer drug delivery
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Lisata Therapeutics to Present at LD Micro Main Event XIX
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics is pioneering new treatments for solid tumors
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics inks global product license deal with Catalent
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics reveals 'encouraging' preliminary data from pancreatic cancer treatment trial
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript
Lisata Therapeutics advances lead cancer drug, expects key trial results by year-end
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update